Document is current
Any future updates will be listed below
-
Authors
Short, Nicholas J.
Jabbour, Elias
Jain, Nitin
Kantarjian, Hagop
-
Funding
Funding for this research was provided by:
MD Anderson Cancer Center (Leukemia SPORE CA100632, Leukemia SPORE CA100632, Leukemia SPORE CA100632, Leukemia SPORE CA100632)
NIH/NCI Cancer Center (Support Grant P30 CA016672, Support Grant P30 CA016672, Support Grant P30 CA016672, Support Grant P30 CA016672)
- License Information
-
More Information
Article History
Received: 26 January 2024
Accepted: 29 April 2024
First Online: 11 May 2024
Declarations
:
: Not applicable.
: Not applicable.
: N.J.S. has served as consultant for Pfizer Inc., GSK, NKARTA, Autolus, and Sanofi, reports receiving research grants from Takeda Oncology, Astellas Pharma Inc., Xencor, Stemline Therapeutics, and NextCure, and has received honoraria from Adaptive Biotechnologies, Novartis, Amgen, Takeda Oncology, Pfizer Inc., Astellas Pharma Inc., Sanofi and BeiGene. E.J. reports receiving research grants and consultancy fees from AbbVie, Adaptive Biotechnologies, Amgen, Ascentage, Bristol Myers Squibb, Genentech, Incyte, Pfizer, and Takeda. N.J. reports receiving research grants from Pharmacyclics, AbbVie, Genentech, AstraZeneca, BMS, Pfizer, ADC Therapeutics, Cellectis, Adaptive Biotechnologies, Precision Biosciences, Fate Therapeutics, Kite/Gilead, Mingsight, Takeda, Medisix, Loxo Oncology, Novalgen, Dialectic Therapeutics, Newave, TransThera Sciences, Novartis, Carna Biosciences, Sana Biotechnology, Kisoji Biotechnology, and has received honoraria from Pharmacyclics, Janssen, AbbVie, Genentech, AstraZeneca, BMS, Adaptive Biotechnologies, Kite/Gilead, Precision Biosciences, Beigene, Cellectis, MEI Pharma, Ipsen, CareDX, MingSight, and Novalgen. H.K. reports receiving research grants from AbbVie, Agios, Amgen, Ariad, Astex, BMS, Cyclacel, Daiichi-Sankyo, Immunogen, Jazz Pharma, Novartis, Pfizer, Actinium, and Takeda.
